Maintenance therapies for asthma are vulnerable to low adherence. Clinicians would benefit from having a validated questionnaire to assess adherence to metered-dose inhaler use in children with asthma. The objective of this study was to design and validate a questionnaire assessing adherence to metered-dose inhaler use, to be filled out by the parents and/or caregivers of children with asthma. The six questions on the Pediatric Inhaler Adherence Questionnaire were obtained from reviewing the literature, from carrying out focus group discussions, and from the researchers' professional experience. We assessed concurrent criterion validity using canister weight change as the gold standard and also assessed test-retest reliability. The questionnaire was administered to the parents/caregivers of 64 children aged 3.6 ؎ 2. 
MATERIALS AND METHODS

Patients
This prospective cohort study was conducted at Clínica Infantil Colsubsidio, a third-level, multidisciplinary teaching hospital located in Bogotá, Colombia. All children (and their parents/caregivers) under 8 years who were diagnosed with persistent asthma, prescribed daily treatment with an MDI, and whose first visit to our outpatient Pediatric Pulmonary Unit took place between November 2005 and March 2006 were included. Parents/caregivers of participating children were native Spanish speakers, with widely varied educational background (at least 5 years of formal education) and socioeconomic status, but with an acceptable reading speed and ability. This unit usually conducts an individual educational intervention for the parents of all children with asthma, the purpose of which is to increase adherence to MDI use by educating parents about asthma as a chronic inflammatory condition. Families were part of this educational intervention while doing the study. All patients were instructed to use a spacer with their MDI. Patients who used MDI without adult supervision and those who depended on more than one adult for their MDI administration were excluded. Study methods were approved by the Clinic's Ethics Committee, and children were enrolled after informed consent was obtained from their parents.
Questionnaire development and scoring
We designed the Pediatric Inhaler Adherence Questionnaire (PIAQ) for this study based on a literature review, [9] [10] [11] [12] [13] [14] answers and observations given by parents of children with asthma in four focus groups, and the professional experience of the researchers. The same experienced facilitator conducted the four focus groups.
Each focus group session lasted 2 hours; all were tape-recorded and transcribed. The focus group facilitator used a standardized script of open-ended questions. The questions posed to the parents in the focus groups were "What things have made it difficult to follow the physician's recommendations about the inhaler use for your asthmatic child?" and "Of these things, which are most significant to you and your child with asthma?" Each comment by a parent was reviewed and grouped with other comments that had a similar subject matter. Two independent raters reviewed the transcripts and classified parents' comments as barriers or nonbarriers to adherence.
Face and content validity were assessed by a multidisciplinary group with ample experience in the treatment of children with asthma-two pediatric pulmonologists, one pediatrician, one physical therapist, and one clinical psychologist. Each member of the team was asked to evaluate the questionnaire by assigning to each item a number from 0 to 2, 0 indicating the item had no importance and 2 indicating it had great importance and needed to be kept on the final instrument. Later, each item's average score was calculated and items were ranked. Those with the lowest scores were considered candidates for removal.
Next, the questionnaire was piloted in four groups of parents of asthmatic children. Each group consisted of the parents of 10 to 15 asthmatic children; the population was a convenience sample enrolled sequen-RODRIGUEZ MARTINEZ ET AL. tially in the same institution where the study was carried out. The pilot studies evaluated item comprehension, ambiguous wording, floor and ceiling effects, the presence of questions with affective loading, and time needed to complete the questionnaire. 15, 16 Items with responses in a certain direction more than 95% of the time were considered candidates for removal. Items were added, modified, or removed based on information collected, until the final questionnaire had the six items shown in Table 1 .
Because the questionnaire inquires about behaviors that could be considered undesirable and thus might be underreported (i.e., failure to use MDI according to medical recommendations), the questionnaire's introduction encourages parents to report those behaviors or attitudes candidly 17 (Table 1 ).
The questionnaire inquires about possible missed and/or additional doses of controller MDI during the preceding 15 days. The questions following those asking about missed/additional doses explore the possible causes of these two types of low adherence. Since individual patients may use different controller MDIs, the questionnaire leaves a blank space to provide the name of the prescribed medication. Because all the study participants were patients from the Plan Obligatorio de Salud (Compulsory Health Insurance Plan), which provided the medication, however, all patients used the same controller MDI (beclomethasone diproprionate).
The questionnaire's final two questions ask about any potential causes of apparently greater MDI use (MDI use by a person other than the patient or, MDI discharges in the air) ( Table 1) .
Answers to questions 1 and 3 were scored from 1 to 5, with lower scores corresponding to greater adherence. Item scores for these two questions were then added for a total score ranging from 2 to 10, with higher scores indicating lesser adherence to MDI. In order to carry out statistical analysis, the answers to questions 1, 3, 5, and 6 were not only collected as ordinal categorical variables, but also as continual variables. The PIAQ was defined as "positive" for nonadherence to MDI use if a score of 3 or higher was obtained, and "negative" for nonadherence if a score of 2 was obtained.
Assessment of the psychometric characteristics of the questionnaire and study development
In order to assess the PIAQ's concurrent criterion validity, adherence to MDI use inferred from answers to the questionnaire was compared with adherence determined by weighing inhaler canisters. In order to calculate this adherence metric as our study's objective "gold standard," inhaler canisters were weighed in triplicate on a digital electronic 0.01-gram precision scale (Ohaus Portable Advanced Electronic Scale) on two different occasions separated by 15 days. Based on the weight difference of the inhaler canisters between each weighing, and taking into account a previous study carried out by our group in order to determine the weight of each discharge of the MDIs used in this study, the actual number of discharges (AND) during the preceding 15 days was determined. On the basis of the time elapsed between each weighing and the number of prescribed discharges, the prescribed number of discharges (PND) was calculated. The percent prescribed taken (PPT) was calculated using the formula (AND/PND) ϫ 100%. According to the gold standard, "positive" for nonadherence to MDI use was defined as a PPT less than 80% or greater than 120% (thus, adherence was defined as a PPT of 80%-120%).
Parents were asked to complete the PIAQ the day the inhaler canisters were weighed for the second time. At the beginning of the visit, the physician introduced the topic of the PIAQ by explaining the desirability of knowing more about the parents' attitudes toward the inhalers. To avoid biasing their answers to the questionnaire, the physician reduced personal contact with the parent/caregiver during data collection, parents were not informed that the aim of the study was to determine the degree of adherence to MDI use, 18 and they also were not informed that inhaler canisters were being weighed. The reported number of discharges (RND) was calculated using the PND and the information given by the parents on the questionnaire. The percentage of reported discharges (PRD) was calculated as RND/AND ϫ 100%.
For example, suppose two MDI discharges every 12 hours were prescribed to a patient, the weight of the MDI at the first visit was 26.5 grams and its weight at the second visit (15 days later) was 22.3 grams, and the parents reported they had forgotten to give five MDI doses. For this example, AND would be (26.5-22. 3)/0.08 ϭ 52.5 discharges, PND would be four discharges per day ϫ 15 days ϭ 60 discharges, PPT would be (52.5/60) ϫ 100 ϭ 87.5%, RND would be 60 Ϫ 5 ϭ 55 discharges, and PRD would be (55/52.5) ϫ 100 ϭ 104.7%. On the basis of these results, this hypothetical patient would be classified as
METERED-DOSE INHALER USE IN ASTHMATIC CHILDREN TABLE 1. PEDIATRIC INHALER ADHERENCE QUESTIONNAIRE (PIAQ)
Parents or guardians often have difficulty giving inhalers to their children with respiratory problems as prescribed by the physician for one reason or another, and we are interested in finding out any problems that occur so that we can understand them better. Please answer the following questions honestly and sincerely:
1. During the past 15 days, how many puffs (how many discharges) of the inhaler has your child missed taking? "positive" for nonadherence according to the PIAQ (score of 3) and "negative" for nonadherence according to the gold standard (PPT between 80% and 120%). In order to assess the test-retest reliability of the questionnaire, each parent completed the questionnaire again 10 to 15 days later. The actual degree of adherence on both test days was assessed by weighing inhaler canisters.
Statistical analysis
In order to compare the PIAQ's score with an objective measurement of adherence, we used Spearman's correlation coefficient to determine the correlation between the questionnaire score and the absolute value of the difference between 100 and PPT, the Kruskal-Wallis followed by Bonferroni's post hoc test, and a similar nonparametric test for a trend (procedure "nptrend," Stata Corporation), to determine whether the PPT was different among different questionnaire scores. We calculated the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and positive likelihood ratio (likelihood that a given test result would be expected in a patient with the target disorder compared to the likelihood that that same result would be expected in a patient without the target disorder) of the PIAQ definition of nonadherence across different levels of prescribed number of discharges compared with the gold standard definition of nonadherence to assess the PIAQ's ability to identify nonadherent patients.
We assessed test-retest reliability by comparing the two questionnaire scores with the Wilcoxon signedrank test, the Lin (r c ) concordance correlation coefficient, 19 and the intraclass correlation coefficient. 20 Using the method proposed by Walter and colleagues 21 yielded a sample size of 64 patients, two methods to be reported in the diagnosis, a kappa for the null hypothesis of 0.5, a kappa for the alternative hypothesis of 0.7, a statistical significance level of 0.05, and a power of 80%.
Statistic analysis was done with Stata 8.0 (Stata Corporation, College Station, TX).
RESULTS
Of the 64 patients included in the study, 34 (53.1%) were boys and 30 (46.9%) were girls. Mean age (ϮSD) of patients was 3.6 Ϯ 2.2 years. The prescribed number of discharges per day (regardless of the actual dose in g of medication) was one discharge in 15 (23.4%) patients, two discharges in 31 (48.4%) patients, three discharges in two (3.1%) patients, and four discharges in the remaining 16 (25.0%) patients. The time elapsed between each weight measurement of inhaler canisters varied from 11 to 19 days, with an average of 15.12 Ϯ 1.34 days.
Time required to fill out the questionnaire ranged from 1 minute to 3 minutes. The median (interquartilic range [IQR]) of the percentage of reported discharges was 102.0% (88.0-110.5%). Descriptive statistics of other continual variables related to MDI are shown in Table 2 . The descriptive statistics of PIAQ scores across different prescribed numbers of discharges are shown in Table 3 .
Questionnaire scores correlated positively with the absolute value of the difference between 100 and percent prescribed taken (Spearman correlation coefficient rho ϭ 0.42, p ϭ 0.001). Differences between PPT among the different questionnaire scores were determined by the Kruskal-Wallis test. A Bonferroni post hoc analysis was performed revealing that the PPT was significantly greater when a score of 2 was obtained than when a score of 6 was obtained on the questionnaire p ϭ 0.03). A nonparametric test for a trend was performed on the four scores, and a significant decrease from the score 2 to 6 was shown (p Ͻ 0.01) (Fig. 1) .
The comparison of the definition of nonadherence according to PIAQ (score of 3 or higher) across different levels of prescribed number of discharges with that of the gold standard (PPT less than 80% or greater than 120%) is shown in Table 4 . The PIAQ's definition of nonadherence yielded sensitivity from 50% to 75%, a positive predictive value from 23.1% to 66.7%, and a likelihood ratio from 1.5 to 5.5 for the detection of nonadherent patients at different prescribed number of discharges levels. 
METERED-DOSE INHALER USE IN ASTHMATIC CHILDREN
In order to determine the leading causes of reduced adherence to MDI use, data were analyzed separately from those parents who had not received the educational intervention and those parents who had received it. In the first group, leading causes reported by parents for administering fewer MDI doses than was recommended by the physician were that they thought their children were better, and that they did not think MDI application was necessary (Table 5 ). Within the second group of parents, leading causes were forgetting and fearing that their children would become dependent on the inhaler (Table 5) . Causes reported as "other reason" were ear tube insertion surgery in one patient and the patient being asleep in another case.
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FIG. 1. Box plots of the percent prescribed taken (PPT) discharges of metered-dose inhaler (MDI)
, stratified according to questionnaire score. Differences between PPT among the different questionnaire scores were determined by the Kruskal-Wallis test. A Bonferroni post hoc analysis was performed revealing that's PPT was significantly greater when a score of 2 was obtained than when a score of 6 was obtained on the questionnaire. A nonparametric test for a trend was performed on the four scores, and a significant decrease from the score 2 to 6 was shown (p Ͻ 0.01). 
DISCUSSION
We assessed the validity of the PIAQ by comparing the adherence of MDI use, as reported by parents on the questionnaire, with the adherence determined by the difference in weight of inhaler canisters as an objective gold standard. Both the average and the median of the percentage of reported discharges were near 100%, which indicates that the number of MDI discharges reported was close to the actual number of discharges administered. A moderate correlation was shown between the PIAQ score and the absolute value of the difference between 100 and percent prescribed taken, as well as a statistically significant difference in PPT among different PIAQ scores. In contrast to the above, the PIAQ's definition of nonadherence yielded sensitivity from 50% to 75%, a positive predictive value from 23.1% to 66.7%, and a likelihood ratio from 1.5 to 5.5 for the detection of nonadherent patients at different levels of prescribed number of discharges. The confidence intervals for the likelihood ratios given were not statistically significant because they always had a range that crossed 1.0. This lack of significance could be due to low power of the study for this analysis, due to the small number of patients included in each level of prescribed number of discharges. Low positive predictive value might be explained by the apparent low prevalence of nonadherence to MDI in this sample (14.2%), since it is well known that predictive values depend not only upon the characteristics of the diagnostic test, but also upon the prevalence of the condition under study in the population. 22 So, we consider that this low predictive positive value and the fact that the range of likelihood ratios crossed 1.0 might be explained by the apparent low prevalence of nonadherence to MDI in our sample, and to low power of the study for this analysis, but that they do not affect the instrument's concurrent criterion validity because of the high correlation shown between PIAQ's measurement of adherence and actual medication usage based on weighing canisters (both the average and the median of the percentage of reported discharges were near 100%). For these reasons, we consider that, when compared to an objective measurement system, the PIAQ accurately estimates the degree of adherence to MDI use, thus showing the instrument's concurrent criterion validity. The fact that we did not observe significant differences between the scores of questionnaires filled out with a 10-to 15-day difference (Lin (r c ) concordance correlation coefficient of 0.82 and an intraclass correlation of 0.83) supports the conclusion that the PIAQ is stable in its ability to measure adherence to MDI use over time (i.e., has good test-retest reliability). However, it is known that the closer the results, the greater the test-retest reliability of a survey instrument, so good test-retest reliability of the PIAQ may have been because of the short time between testing and retesting, and longer interval of time may not have shown the same results.
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Many other studies have shown that parents tend to overreport their medication usage of controller, preventable medication. We feel that parents are more prone to overreport their medication usage when they feel they are being judged by their physician. Instead of that, when completing the PIAQ, parents were allowed to say what they felt, without judging or criticizing them, mainly because of its introduction that encourages them to report behaviors that could be considered undesirable (i.e., failure to use MDI according to medical recommendations) candidly. Additionally, noncompliance and overreporting sometimes result from difficult to measure issues such as insufficient clarity in giving instructions, and not good enough physician-patient relationship and communication, two headline mistakes that we are continuously trying to avoid.
Two factors should be considered before using the PIAQ in clinical practice. First, it is important to make sure that the patient and his or her parents have received adequate instruction about regular MDI use before cataloguing them as nonadherent to MDI therapy. Second, questions 5 and 6 of the PIAQ assess po- tential causes of increased MDI use (application of MDI to a person other than the patient and MDI discharges into the air). It was important for us to include these two questions in the PIAQ when validating it; however, they could be omitted when using the questionnaire in clinical practice, because the first four questions are the ones that directly assess MDI use and reasons for nonadherence. The causes for low adherence reported by parents who had not received the educational intervention referred to earlier are similar to those found by us in a previous study. 23 In that study we found that two of these causes (the fact that parents consider that asthma medications should only be administered when their children have respiratory symptoms, and the fact that parents fail to recognize that asthma exacerbations can be avoided if medications are administered during intercritical periods) were independent risk factors for parents repeatedly consulting the emergency service due to their children's asthma. These findings reinforce the concept that low adherence to asthma medications is associated with increased morbidity and costs derived from the disease. 1,2 Moreover, the fact that these causes for low adherence reported by parents who had not received the individual educational intervention are different from those reported by parents who had already received it (for whom the main cause was forgetting to administer the dose) shows the impact that a short interventional education at the moment of initial consultation has on MDI adherence.
The study's limitations include the fact that the PIAQ assesses adherence to MDI use in a short period of time (only the 15 preceding days). However, this period of time is enough to determine whether there is favorable clinical and functional response to the administration of inhaled steroids, 24 although it is true that some research has shown that inhaled steroids for asthma may take 4 to 6 weeks to result in a maximal effect. 25 For this reason, the PIAQ score would probably be even more helpful if used in conjunction with a clinical evaluation visit done at 4 to 6 weeks out after starting an inhaled steroid.
Another limitation could be our choice of gold standard used to evaluate the PIAQ. Counting or measuring medications and determining inhaler canister weight have been described as useful methods and objective parameters for validation of self-reports and asthma diaries. 1 A disadvantage of this method is that it does not provide information about the daily pattern of MDI use. It also cannot be carried out if patients do not return inhaler canisters. This method is vulnerable to deceit by patients if they, for example, intentionally discharge the MDI into the air ("dumping") before the canister is weighed. 26 In this study, however, parents were not told that the aim of the study was to estimate adherence to MDI use or that inhaler canisters were being weighed. Thus, it is unlikely that parents would have intentionally discharged the MDI to simulate better adherence.
The PIAQ is limited, as are all self-report questionnaires, by being based on the memory and social biases of those who fill it out. We believe our study methods minimized these problems because of the short period of time assessed (15 days) and the encouragement in the introduction to be honest and sincere in answering. 17 Moreover, the PIAQ has only been validated in a Spanish-speaking population, and future studies in English-speaking populations will need to examine validation in English. Furthermore, future studies are needed to assess the psychometric characteristics of the PIAQ using electronic medication monitors as an objective parameter of comparison, the validity of the PIAQ in populations with different prevalence of MDI use adherence, and the validity of the PIAQ as an adherence measure over longer periods of time.
Our findings suggest that the PIAQ is a valid instrument for assessing adherence to MDI use in children with asthma. It showed adequate concurrent criterion validity when compared to an objective measurement system and adequate test-retest reliability. Moreover, this instrument is brief, inexpensive, and easy to perform. It can easily be used in everyday clinical practice and for future research purposes.
